

**Remarks/Arguments**


The specification has been amended to incorporate the priority claim.

The claims have been amended to remove multiple dependencies and to otherwise place the claims in an appropriate U.S. format. Thus, claims 1 and 12 are as originally presented. Claims 2, 3, 4, 5, 6, 8, and 11 are currently amended. Claims 7, 9, and 10 are cancelled. Claim 13 is new. No new matter has been added by these amendments.

Applicants believe the application is in condition for allowance and reserve the right to prosecute any cancelled subject matter in timely filed continuation applications.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100869-1P US.

Respectfully submitted,



---

Name: Heidi Berven  
Dated: September 21, 2005  
Reg. No.: 48,951  
Phone No.: 781-839-4336  
Global Intellectual Property, Patents,  
AstraZeneca R&D Boston,  
35, Gatehouse Drive,  
Waltham,  
MA 01760